Masimo (NASDAQ:MASI) updated its FY 2019
Pre-Market earnings guidance on Tuesday. The company provided EPS guidance of 3.18 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.17. The company issued revenue guidance of $934-937 million, compared to the consensus revenue estimate of $947.01 million.Masimo also updated its FY 2020
Pre-Market guidance to 3.56-3.56 EPS.
A number of research firms recently commented on MASI. Piper Jaffray Companies reiterated an overweight rating and set a $175.00 price objective (up previously from $161.00) on shares of Masimo in a research note on Tuesday, December 17th. BidaskClub upgraded shares of Masimo from a hold rating to a buy rating in a research note on Monday, December 16th. UBS Group raised their price objective on shares of Masimo from $180.00 to $190.00 and gave the company a buy rating in a research note on Wednesday. Finally, ValuEngine lowered shares of Masimo from a buy rating to a hold rating in a research note on Wednesday, October 2nd. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Masimo currently has a consensus rating of Buy and an average price target of $163.42.
Masimo stock traded up $2.82 during mid-day trading on Wednesday, hitting $166.85. The company’s stock had a trading volume of 2,473 shares, compared to its average volume of 387,400. The stock has a market capitalization of $8.68 billion, a P/E ratio of 55.02, a P/E/G ratio of 2.02 and a beta of 1.13. Masimo has a twelve month low of $111.33 and a twelve month high of $165.48. The stock’s fifty day moving average price is $157.98 and its two-hundred day moving average price is $152.03.
Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $0.76 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.03. The firm had revenue of $229.01 million for the quarter, compared to analyst estimates of $221.92 million. Masimo had a net margin of 20.83% and a return on equity of 17.32%. The firm’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.71 earnings per share. As a group, analysts anticipate that Masimo will post 3.17 earnings per share for the current year.
In related news, EVP Anand Sampath sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $155.00, for a total value of $2,325,000.00. Following the completion of the transaction, the executive vice president now owns 27,518 shares of the company’s stock, valued at approximately $4,265,290. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Thomas Samuel Mcclenahan sold 500 shares of the firm’s stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $159.29, for a total transaction of $79,645.00. Following the completion of the transaction, the executive vice president now directly owns 5,607 shares of the company’s stock, valued at approximately $893,139.03. The disclosure for this sale can be found here. Insiders sold a total of 56,000 shares of company stock valued at $8,683,715 in the last ninety days. Company insiders own 11.50% of the company’s stock.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
See Also: What does RSI mean?
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.